UIA
IOVA icon

Ulland Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Ulland Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed – – 235
2025
Q2 		$0 Hold
100
– – ﹤0.01% 224
2025
Q1 		$0 Hold
100
– – ﹤0.01% 224
2024
Q4 		$1K Hold
100
– – ﹤0.01% 203
2024
Q3 		$1K Hold
100
– – ﹤0.01% 194
2024
Q2 		$1K Hold
100
– – ﹤0.01% 212
2024
Q1 		$1K Buy
+100
New +$1.16K ﹤0.01% 218

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ulland Investment Advisors's IOVA Position: Q3 2025 in Review

Ulland Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 100 shares.

Ulland Investment Advisors first reported a position in IOVA in Q1 2024 and held it in 6 quarters. The position peaked at $1K in Q4 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Ulland Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Ulland Investment Advisors sold 100 Iovance Biotherapeutics shares in Q3 2025.
  • Ulland Investment Advisors first reported a position in Iovance Biotherapeutics in Q1 2024 and held it in 6 quarters.
  • Ulland Investment Advisors's Iovance Biotherapeutics position peaked at $1K in Q4 2024.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Ulland Investment Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.